Table 1 Evolution of therapy in patient 1
Regimen | Duration of therapy (mo) | Best response | Reason for stopping |
|---|---|---|---|
Bortezomib/thalidomide/dexamethasone (VTd) | 5 (Aug–Dec 2013) | CR | Auto-HSCT |
VTd consolidation | 2 (Jun–Jul 2014) | CR | Started maintenance |
Lenalidomide maintenance | 18 (Aug 2014–Jan 2016) | CR | PD |
Carfilzomib/lenalidomide/dexamethasone (KRd) | 3 (March–May 2016) | PD | PD |
Bortezomib/cyclophosphamide/dexamethasone (VCd) | 3 (Aug–Oct 2016) | PR | PD |
Bortezomib/dexamethasone/cisplatin/doxorubicin/cyclophosphamide (DV-PACE) | 2 (Dec 2016–Jan 2017) | VGPR | Auto-HSCT |
Bortezomib maintenance | 11 (Apr 2017–Feb 2018) | VGPR | PD |
Elotuzumab/lenalidomide/dexamethasone (ERd) | 5 (Mar–Aug 2017) | PD | PD |
Daratumumab/bortezomib/dexamethasone (DVd) | 6 (Sep 2017–Feb 2018) | VGPR | t(11;14) acquired |
Venetoclax/carfilzomib/dexamethasone (VenKd) | 6 (Mar–Sep 2019) | CR | PD |
Cyclophosphamide/carfilzomib/dexamethasone (CKd) | 2 (Oct 2019–present) | NA | NA |